Roles of transient receptor potential canonical channels in tumors

doi:10.3760/cma.j.issn.1673-422X.2015.07.012

Abstract

Abstract: Transient receptor potential (TRP) channels as an important nonselective cation channels family mainly permeate Ca2+, Na+ and other cations. TRPC channel is a subtribe of TRP family which regulates the second messenger of Ca2+ concentration and variety of protease activity, and which can directly or indirectly affect the biological behavior of cells. Recently, more and more evidences have certificated the TRPC channels affect the tumorigenesis and development, such as regulation of proliferation, differentiation, migration, apoptosis and resistance of chemotherapeutic agents during cancer progression.

Key words: Neoplasms, Transient receptor potential canonical channel

Wang Linjun, Hua Dong. Roles of transient receptor potential canonical channels in tumors[J]. Journal of International Oncology, 2015, 42(7): 522-524.

References

［1］ Nesin V, Tsiokas L. TRPC1［J］. Handb Exp Pharmacol, 2014, 222: 15-51. ［2］ Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy［J］. Circ Res, 2011, 108(2): 265-272. ［3］ Rohacs T. Regulation of transient receptor potential channels by the phospholipase C pathway［J］. Adv Biol Regul, 2013, 53(3): 341-355. ［4］ El Hiani Y, Ahidouch A, OuadidAhidouch H, et al. Extracellular signalregulated kinases 1 and 2 and TRPC1 channels are required for calciumsensing receptorstimulated MCF7 breast cancer cell proliferation［J］. Cell Physiol Biochem, 2009, 23(46): 335-346. ［5］ Tajeddine N, Gailly P. TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling［J］. J Biol Chem, 2012, 287(20): 16146-16157. ［6］ Bomben VC, Turner KL, Sontheimer H, et al. Transient receptor potential canonical channels are essential for chemotactic migration of human malignant gliomas［J］. J Cell Physiol, 2011, 226(7): 1879-1888. ［7］ Yang SL, Cao Q, Wang YZ, et al. Transient receptor potential channel C3 contributes to the progression of human ovarian cancer［J］. Oncogene, 2009, 28(10): 1320-1328. ［8］ Saito H, Minamiya Y, Ogawa J, et al. Expression of the transient receptor potential channel c3 correlates with a favorable prognosis in patients with adenocarcinoma of the lung［J］. Ann Surg Oncol, 2011, 18(12): 3377-3383. ［9］ Zhang Q, He J, Wang D, et al. Expression of transient receptor potential canonical channel proteins in human nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2010, 13(6): 612-616. ［10］ Jiang HN, Zeng B, Xu SZ, et al. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human nonsmall cell lung cancer［J］. PLoS One, 2013, 8(6): e67637. ［11］ Zeng B, Yuan C, Xu SZ, et al. TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis［J］. Curr Cancer Drug Targets, 2013, 13(1): 103-116. ［12］ Jiang HN, Zeng B, Zhang Y, et al. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human nonsmall cell lung cancer［J］. PLoS One, 2013, 8(6): e67637. ［13］ Ma X, Cai Y, Yao X, et al. Transient receptor potential channel TRPC5 is essential for Pglycoprotein induction in drugresistant cancer cells［J］. Proc Natl Acad Sci USA, 2012, 109(40): 16282-16287. ［14］ Ma X, Chen Z, Hua D, et al. Essential role for TrpC5containing extracellular vesicles in breast cancer with chemotherapeutic resistance［J］. Proc Natl Acad Sci USA, 2014, 111(17): 6389-6394. ［15］ Ding X, He Z, Wang Y, et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma［J］. J Natl Cancer Inst, 2010, 102(14): 1052-1068. ［16］ Ge R, Tai Y, Wang Y, et al. Critical role of TRPC6 channels in VEGFmediated angiogenesis［J］. Cancer Lett, 2009, 283(1): 43-51. ［17］ Cai R, Ding X, Wang Y, et al. Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells［J］. Int J Cancer, 2009, 125(10): 2281-2287. ［18］ Ding X, He Z, Wang Y, et al. Targeting TRPC6 channels in oesophageal carcinoma growth［J］. Expert Opin Ther Targets, 2010, 14(5): 513-527. ［19］ Yue D, Wang Y, Ren CS, et al. Expression of TRPC6 in benign and malignant human prostate tissues［J］. Asian J Androl, 2009, 11(5): 541-547. ［20］ Wang Y, Yue D, Li K, et al. The role of TRPC6 in HGFinduced cell proliferation of human prostate cancer DU145 and PC3 cells［J］. Asian J Androl, 2010, 12(6): 841-852.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.